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ABSTRACT 
 
Background: Helicobacter pylori infection is usually acquired in early childhood and is 
rarely resolved spontaneously. Eradication therapy is currently recommended virtually to 
all patients. Usually the first and second therapies are prescribed without knowing the 
antibiotic resistance of the bacteria. Thus, it is important to know the primary resistance in 
the population to choose a regimen with at least 80% efficacy, in preventing induction of 
resistant strains. Although dyspeptic symptoms are one of the main indications for therapy, 
the symptomatic gain from therapy has been only modest.  
 
Aim: This study evaluates the primary resistance of H. pylori among patients in primary 
health care throughout Finland, the efficacy of three eradication regimens among these 
patients, the symptomatic response to successful therapy, and the effect of smoking on 
gastric histology and humoral response in H. pylori-positive patients. Based on this study, 
a first-line eradication therapy in Finland could be recommended. 
 
Patients and methods: A total of 23 endoscopy referral centres located throughout 
Finland recruited 342 adult patients with positive rapid urease test results, who were 
referred to upper gastrointestinal endoscopy from primary health care. During endoscopy, 
one biopsy for culture and two for histology were taken from the gastric antrum and body.  
A blood sample for serology was taken. The patients were randomized to receive a seven-
day regimen, comprising 1) lansoprazole 30 mg b.d., amoxicillin 1 g b.d. and 
metronidazole 400 mg t.d. (LAM), 2) lansoprazole 30 mg b.d., amoxicillin 1 g b.d. and 
clarithromycin 500 mg b.d. (LAC) or 3) ranitidine bismuth citrate 400 mg b.d., 
metronidazole 400 mg t.d. and tetracycline 500 mg q.d. (RMT). The eradication results 
were assessed, using the 13C-urea breath test 4 weeks after therapy. The negative breath 
test was confirmed with serology and the positive test with a new endoscopy with 
histological samples and H. pylori culture. The patients completed a symptom 
questionnaire before and a year after the therapy. 
 
Main results and conclusions:  
1. Resistance 
Resistance in H. pylori was successfully assessed with the E-test in 292 cases. Primary 
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resistance to metronidazole was 38%, 48% among women and 25% among men. In 
women, metronidazole resistance correlated with previous use of antibiotics for 
gynaecologic infections and alcohol consumption. Resistance rate to clarithromycin was 
only 2% and was associated with previous antibiotics for dental and respiratory infections. 
Thus, metronidazole-based therapies cannot be recommended for women unless the 
sensitivity of H. pylori is known. 
 
2. Eradication results 
The eradication result could be assessed in 329 cases. Eradication therapy was successful 
in 78% of intention-to-treat analysis in LAM, 81% in RMT and 91% in LAC. In 
metronidazole-sensitive cases, the cure rates with LAM, RMT and LAC were similar 
(93%, 91% and 95%), whereas in metronidazole resistance, LAM and RMT were inferior 
to LAC (53%, 67% and 84%). Clarithromycin resistance reduced the eradication rate from 
84% to 43%. Previous antibiotic therapies reduced the efficacy of LAC, to the level of 
RMT.  Thus, LAC is the best choice for first-line eradication therapy. 
 
3. Symptoms 
The symptomatic response to successful eradication of H. pylori could be assessed in 216 
patients. Dyspeptic symptoms in the Gastrointestinal Symptoms Rating Scale (GSRS) were 
analysed. All dyspeptic symptoms were decreased; the mean reduction was 30.5%. In 
logistic regression analysis, duodenal ulcer, gastric antral neutrophilic inflammation and 
age from 50 to 59 years independently predicted greater decrease in dyspeptic symptoms 
as a whole. The effect of eradication on dyspeptic symptoms was only modest and 
comparable to that in previously reported results with placebo. 
 
4. Smoking 
The effect of smoking on gastric histology and humoral response to H. pylori was analysed 
in 318 patients. In the gastric body, smokers had milder neutrophilic and chronic 
inflammation and less atrophy and in the antrum denser H. pylori load. Smokers also had 
lower IgG antibody titres against H. pylori and a smaller proportional decrease in 
antibodies after successful eradication. Smoking slows the progression of atrophy in the 
gastric body and triples the risk of duodenal ulcers (32%) vs. 11% among nonsmokers. 
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LIST OF ABBREVIATIONS 
 
ASA acetylsalicylic acid  
b.d. twice per day 
CI confidence interval 
DU duodenal ulcer 
GSRS Gastrointestinal Symptoms Rating Scale 
GU gastric ulcer 
LAC lansoprazole 30 mg b.d., amoxicillin 1 g b.d. and clarithromycin 500 mg b.d. 
LAM lansoprazole 30 mg b.d., amoxicillin 1 g b.d. and metronidazole 400 mg t.d. 
MALT mucosa-associated lymphoid tissue 
MIC minimal inhibitory concentration  
NNT number needed to treat 
NSAID nonsteroidal anti-inflammatory drug 
NUD nonulcer dyspepsia  
OR odds ratio 
q.d. four times per day 
PPI proton pump inhibitor 
PU peptic ulcer 
PUD peptic ulcer disease 
RBC ranitidine bismuth citrate 
RMT ranitidine bismuth citrate 400 mg b.d., metronidazole 400 mg t.d., and 
tetracycline 500 mg q.d. 
RUT rapid urease test 
t.d. three times per day 
UBT 13C-urea breath test 
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INTRODUCTION 
 
It has been estimated that over half of mankind is infected by Helicobacter pylori. In the 
developing countries, 80% of the adults carry H. pylori. Along with improvements in 
hygiene, infections have become less frequent, and in the Western countries H. pylori has 
become an infection of middle-aged and elderly people. Helicobacter pylori is mostly 
acquired in early childhood, most probably from another family member. Very seldom will 
H. pylori be cleared spontaneously. After the primary infection, the patient develops 
symptomatic gastritis; thereafter, in most cases, the helicobacter leads a quiet life in the 
gastric mucosa for the rest of the host’s life. However, about 10–20% of people carrying H. 
pylori will develop gastrointestinal symptoms of infection. The infection can lead to a 
peptic ulcer (PU) and, in rare cases, to gastric malignancy.  
 
Even though H. pylori is sensitive to many antibiotics, the niche it lives in makes 
eradication difficult. Only regimens consisting of at least two antibiotics and a proton 
pump inhibitor (PPI) or bismuth have achieved efficacies of over 90%. Amoxicillin, 
tetracycline, metronidazole and clarithromycin are the most used antibiotics. Antibiotic 
resistance is an important predictor for success of the eradication therapy. Usually the first 
eradication therapy is given without knowing the sensitivity of the bacteria. Thus, choosing 
the most effective first-line therapy requires knowledge of the primary antibiotic resistance 
of H. pylori in the population. While resistance of H. pylori to amoxicillin and tetracycline 
is very rare and very rarely develops after a failed therapy, resistance to metronidazole and 
clarithromycin is an important issue. Resistance to metronidazole varies widely in different 
parts of the world, from 20% in some Western countries to over 80% in the developing 
countries. Women have resistant strains more often than men. Resistance to clarithromycin 
is common, up to 20%, in countries with liberal antibiotic policies, such as those in 
Southern Europe, but less than 10% in Northern countries with more strict antibiotic 
policies. Recently, fluoroquinolones, such as levofloxacin, have been proven effective both 
in naïve cases and after eradication failures. 
 
Since the first indications for H. pylori eradication therapy were peptic ulcer disease (PUD) 
and malignant and premalignant conditions, the Maastricht III consensus report now 
recommends eradication therapy for everyone infected and even test-and-treat strategy for 
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uninvestigated dyspepsia (Malfertheiner et al. 2007). Knowing that in nonulcer dyspepsia 
(NUD) about 10% of the dyspeptic symptoms are caused by H. pylori infection, most of 
the symptomatic benefit comes from the placebo effect. PUD can in most cases be cured 
by H. pylori eradication. For ulcers among users of nonsteroidal anti-inflammatory drugs 
(NSAIDs), H. pylori has an additive effect and eradication is recommended. 
 
In addition to H. pylori, smoking predisposes to PU both by enhancing ulcerogenic factors 
and hampering restoration of mucosal lesions. It has also been associated with malignant 
changes induced by H. pylori. 
 
Helicobacter pylori has coexisted with mankind since prehistoric times, thus one could 
also expect that it may be beneficial to its bearer.  However, no proof of this is available, 
although H. pylori has been suggested to protect from allergy.   
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REVIEW OF THE LITERATURE 
 
HISTORY 
 
In the year 1875 G. Bottcher in collaboration with M. Letulle, after finding bacteria 
colonizing gastric ulcers (GUs) and ulcer margins, regarded the bacteria responsible for the 
ulcer (Kidd and Modlin 1998). Then in 1889 W. Jarowski found spiral organisms in gastric 
washings, named them Vibrio rugula and suggested they were pathogenic in gastric 
diseases (Konturek 2003). In 1896 H Salomon could transfer the infection to mice, and 10 
years later W. Krieniz associated the bacteria with gastric cancer. J.M. Luck discovered 
gastric mucosal urease as early as 1924. Investigations continued and in 1940 F.D. Gorham 
postulated gastric acidophilic bacteria as an aetiologic agent in PUD and treated PUs with 
bismuth (Kidd and Modlin 1998). However, E.D. Palmer later could not find these bacteria 
in vacuum biopsies in 1088 patients, and the issue was forgotten for 30 years (Palmer 
1954). Finally, Robin Warren in 1979 rediscovered the bacterium, and he with Barry 
Marshall, over 100 years after the first description, cultured it and by Koch’s postulates 
proved it to be the cause of gastritis and subsequently of PU. This was the beginning of a 
new era in gastroduodenal diseases. 
 
 
HELICOBACTER PYLORI INFECTION 
Bacteriology 
Helicobacter pylori is a multiflagellated spiral bacterium in the Helicobacteraceae family, 
which in turn belongs to the Epsilonproteobacteria class (http://www.bacterio.cict.fr). The 
acid gastric mucus layer is its natural niche. It has been found in the duodenum with gastric 
metaplasia, and also in dental plaques and faeces. It is microaerophilic and capnophilic. In 
producing ammonia with its urease enzyme, it becomes adjusted to the acid milieu and 
thrives poorly in the nonacid mucosa of atrophic gastritis.  
 
Species: H. pylori, Genus: Helicobacter, Family: Helicobacteraceae, Order: 
Campylobacterales, Class: Epsilonproteobacteria, Phylum: Proteobacteria, Kingdom: 
Bacteria. 
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Epidemiology 
Helicobacter infection is in most cases acquired in early childhood (Feldman et al. 1998). 
When the bacterium is found in the gastric epithelium, dental plaques, vomit and faeces, 
the mode of transmission can be oral-oral, gastro-oral and faecal-oral; the main route is not 
clear (Vaira et al. 2001). Overcrowding, large families, poverty and low hygienic standards 
during childhood predispose to the infection. When hygiene was improved along with 
rising living standards, the incidence declined accordingly (Ahmed et al. 2007). Clearance 
of the infection is a rare event: less than 1% per year (Kosunen et al. 1997). Thus, when 
the older people still have the infection and the younger ones seldom catch it, the cohort 
effect is seen in the developed countries. In Finland less than 10% of children harbour H. 
pylori, compared with 70-80% of those 70 years of age or over (Rehnberg-Laiho et al. 
1998; Rautelin and Kosunen 2004). In Finland the rate of adult acquisition of new H. 
pylori infection is very low, app. 1% per year as in other Western countries (Seppälä et al. 
1992; Sipponen et al. 1996; Gisbert 2005). Helicobacter pylori is still a major issue in the 
developing countries, but the prevalence will eventually decline as it has already done in 
the developed countries (Tkachenko et al. 2007). 
 
 
ANTIBIOTIC RESISTANCE 
 
The antimicrobial resistance of H. pylori varies throughout the world. The antibiotics most 
often used in eradication therapy are amoxicillin, metronidazole, tetracycline, 
clarithromycin and recently levofloxacin. Resistance is the most important factor impairing 
eradication therapy. 
 
Metronidazole 
Metronidazole is metabolized by oxygen-sensitive nitroreductase enzymes of anaerobic 
bacteria into toxic metronidazole radicals that react with proteins, DNA and RNA, 
resulting in the death of the bacteria. Mutations in these genes may block the effect of 
nitroimidazoles. In H. pylori the main enzyme is oxygen-insensitive nicotineamide adenine 
dinucleotide phosphate (NADPH) nitroreductase. The toxic nitrosoderivatives this enzyme 
produces are not reoxidized by existing molecular oxygen, and cell damage ensues. 
Metronidazole resistance is mostly associated with mutations in the rdxA gene that 
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encodes oxygen-insensitive NADPH nitroreductase. Mutations in the frxA gene, which 
encodes NAD(P)H-flavin oxidoreductase enhances the effect (van der Wouden et al. 2000; 
Bereswill et al. 2003). This complexity in nitroimidazole metabolism means that 
metronidazole resistance is not either/or. Furthermore, mutations in the rdxA or frxA genes 
alone do not explain the resistance (Chisholm and Owen 2003; Marais et al. 2003). As a 
result, metronidazole-based therapies can eradicate metronidazole-resistant strains, 
although not as effectively as sensitive strains (Lind et al. 1999). 
 
Resistance to metronidazole in Europe and the USA is between 20% and 40%, but wide 
use of metronidazole for parasitic infections increases resistance in the developing 
countries up to 80% (Glupczynski 1998; Glupczynski et al. 2001; Osato et al. 2001).  
Local differences in Europe exist; e.g. in the southern part resistance is 40%, compared 
with 30% in the North. Immigrants bring their own helicobacters with them; thus people 
coming from the developing countries have more resistant strains (Banatvala et al. 1994; 
Glupczynski et al. 2001). In Japan, exceptionally low resistance rates are seen (12.4%), 
again with local differences (Kato et al. 2000). Women more often harbour resistant strains 
than men, most probably due to therapies for gynaecologic infections (Glupczynski et al. 
2001; Bruce et al. 2006). In a large European study, metronidazole resistance among 
children was similar to that (25%) found among adults (Koletzko et al. 2006). Figure 1 
shows the resistance frequencies found in various European countries. 
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 Figure 1. Metronidazole resistance in Europe 
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1. (Dzierzanowska-Fangrat et al. 2005), 2. (Loivukene et al. 2002), 3. (Boyanova et 
al. 2002) 4. (Xia et al. 1996), 5. (Toracchio and Marzio 2003), 6. (Dite et al. 2002), 
7. (Lerang et al. 1997) 8. (Gisbert and Pajares 2001), 9. (Chisholm et al. 2007), 10. 
(Cabrita et al. 2000), 11. (Wolle et al. 2002), 12. (Boyanova et al. 2008), 13. (de 
Korwin 2004), 14. (Storskrubb et al. 2006), 15. (Janssen et al. 2006) 
 
Clarithromycin 
Resistance to macrolides is in most cases caused by one of three single-point mutations in 
the peptidyltransferase region of the 23S rRNA gene, mostly mutation A2143G or 
A2142G, when the adenine residue is replaced by guanine and less commonly by a 
cytosine residue (A2142C) (Oleastro et al. 2003). These mutations decrease macrolide 
binding to the ribosomes. 
 
Resistance to clarithromycin has been much less frequently observed than resistance to 
metronidazole. In a large European survey, resistance to clarithromycin was 9.9%. Again, 
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clear differences between Southern and Northern Europe were seen. Of those born in 
Southern Europe, 18.4% had resistant strains, compared with 9.3% in central Europe and 
4.2% in Northern Europe (Glupczynski et al. 2001). In Norway and Sweden, even smaller 
figures were found  (< 3%) (Lerang et al. 1997; Jaup et al. 1998; Storskrubb et al. 2006). 
Children show the same geographical distribution: the resistance frequency among 
Southern European children was 2.2 times that of Northern European children. Younger 
children, compared with older children, also more often had resistant helicobacters 
(Cabrita et al. 2000; Koletzko et al. 2006). In the USA, about 10% of helicobacters are 
clarithromycin-resistant (Osato et al. 2001; Meyer et al. 2002). Resistance can be seen as a 
direct consequence of increased macrolide consumption (McMahon et al. 2003). 
Clarithromycin resistance emerged in Estonia after clarithromycin became available, while 
the resistance frequencies in Japan correlated with macrolide sales (Loivukene et al. 2002; 
Perez Aldana et al. 2002). Thus, it is clear that clarithromycin resistance has increased and 
will continue to do so (Chisholm et al. 2007; De Francesco et al. 2007). Resistance after 
monotherapy with clarithromycin was 32% (Peterson et al. 1993). Figure 2 shows the 
resistance frequencies found in various European countries. 
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 Figure 2. Clarithromycin resistance in Europe 
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1. (Toracchio and Marzio 2003), 2. (Tankovic et al. 2001), 3. (Buzas et al. 2007), 4. 
(Dzierzanowska-Fangrat et al. 2005), 5. (Cabrita et al. 2000), 6. (Boyanova et al. 
2002), 7. (Chisholm et al. 2007), 8. (Gisbert and Pajares 2001), 9. (Xia et al. 1996), 
10. (Dite et al. 2002), 11. (Loivukene et al. 2002), 12. (Wolle et al. 2002), 13. 
(Storskrubb et al. 2006), 14. (Janssen et al. 2006), 15. (Lerang et al. 1997). 
 
Amoxicillin 
Fever than 1% of helicobacters are resistant to amoxicillin (Megraud 2004). The 
mechanism is based on mutations in the genes coding for penicillin-binding protein and, in 
consequence, decreased affinity for amoxicillin leads to decreased accumulation of the 
antibiotic (Co and Schiller 2006; Gerrits et al. 2006). Still, in a Japanese study H. pylori 
strains resistant to amoxicillin appeared after the year 1996, while insensitive strains also 
increased, the importance of this phenomenon remains to be seen (Watanabe et al. 2005). 
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Tetracycline 
Resistance to tetracycline is also very low, less than 1% (Wolle et al. 2002; Megraud 
2004). A triple mutation AGA 926-928→TTC in the 16S rRNA gene is responsible. Since 
one or two mutations are not capable of producing resistance, tetracycline resistance is 
very rare despite its wide use (Gerrits et al. 2003).  
 
Fluoroquinolones 
Of the fluoroquinolones on the Finnish market, levofloxacin has been tested in H. pylori 
eradication regimens. Resistance to fluoroquinolones is based on point mutations in the 
quinolone resistance-determining regions of gyrA. Due to the wide use of 
fluoroquinolones, resistance is already high in France (17%), Belgium (16.8%), and 
Portugal (up to 20.9%) and still higher among those with previous fluoroquinolone 
therapies (Cabrita et al. 2000; Bogaerts et al. 2006; Carothers et al. 2007; Cattoir et al. 
2007). Of the H. pylori strains collected in Japan from 2001 to 2004, 15% were resistant 
(Miyachi et al. 2006).  In Germany, resistance is currently increasing (primarily 9.5%) and 
is exceptionally high among patients who had a previous failed eradication therapy not 
including a fluoroquinolone (17.1%). Moreover, most fluoroquinolone-resistant strains 
were also resistant to metronidazole and clarithromycin (Glocker et al. 2007b). This makes 
rescue therapies with fluoroquinolones less favourable and at least will favour 
susceptibility testing before the attempt. Resistance is currently increasing so rapidly that 
rates found a few years earlier are no longer relevant in deciding on the use of 
fluoroquinolones. 
 
Rifabutin 
Rifabutin is used as a rescue therapy in metronidazole- and clarithromycin-resistant H. 
pylori cases. Resistance to rifabutin is extremely rare. In a German study only 1.4% of 
1585 isolates were rifampicin-resistant (minimal inhibitory concentration (MIC) > 4 
µg/ml) and most were also rifabutin-resistant (Glocker et al. 2007a). Mutations in the rpoB 
gene are responsible for the resistance (Heep et al. 2000b). 
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Dual resistance to both metronidazole and clarithromycin 
Resistance to both the antibiotics most used in eradication therapy has become an 
important issue.  In London, where immigrants make up a large proportion of the 
population, dual resistance is as high as 8% (Elviss et al. 2005) In a multicentre study in 
the USA, 5% of the strains collected from 1998 to 2002 were dual-resistant (Duck et al. 
2004). Wong et al. (2003) in Hong Kong found a dual resistance of 8.7%. In the SHARP 
study, the dual resistance varied between 0% and 6.9% (2.4% in men and 6.9% in women) 
during 1993–1999 (Meyer et al. 2002). In a recent study, as many as 77.6% of the strains 
were dual-resistant after a failed therapy with clarithromycin and metronidazole (Branca et 
al. 2004). Finally, patients can harbour mixed H. pylori strains, and in these cases the risk 
for dual resistance is higher (Cellini et al. 2006). 
 
Secondary resistance 
After a failed therapy, the resistance rate is high; e.g. in an Italian study the rate was 69.8% 
for metronidazole and 82.3% for clarithromycin (Toracchio and Marzio 2003). In a large 
German study, 66–75% of the strains were resistant to metronidazole and 49–58% to 
clarithromycin, but none to amoxicillin after a failed therapy in 554 patients. The alarming 
aspect is that 85–89% of the metronidazole-resistant strains were also clarithromycin-
resistant (Heep et al. 2000a).  Figures in the study of Branca et al. (2004) were similar. In a 
Japanese study, secondary resistance to gatifloxacin was 47.9% (Nishizawa et al. 2006). 
 
 
HELICOBACTER PYLORI AND GASTRODUODENAL DISEASES 
Gastritis 
After arriving in the stomach, H. pylori penetrates the mucous layer and adheres to the 
epithelial cells by adhesins. In some cases, the bacterium can penetrate the lamina propria; 
it also produces water-soluble antigens capable of penetrating the basement membrane. 
These and interleukins (e.g. interleukin-8) from the gastric epithelial cells attract 
polymorphonuclear leucocytes. Antigen-presenting cells activate B and T lymphocytes and 
plasma cells, and antibody production begins, at first the IgM type, thereafter the IgA and 
IgG types (Andersen 2007). After a recently acquired H. pylori infection, the gastric 
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histology shows acute and chronic inflammatory cells. Organized lymphoid follicles have 
also been observed. Graham et al. (2004) showed that in 2 weeks the histology was very 
much like that seen in chronic infection. Acute infection produces achlorhydria for several 
months. Thereafter, the acid secretion recovers and, in patients prone to DU, will remain 
raised, while in those developing atrophic gastritis, it will diminish over decades. 
 
Helicobacters with the cytotoxin associated gene (Cag) pathogenicity island (PaI) via 
increasing interleukin-8 production induce more intensive inflammation in the gastric 
mucosa. Also the outer inflammatory protein (OipA) and in East Asian countries, the RNA 
polymerase β-subunit variant of H. pylori promote interleukin-8 production. Further, the 
immune response of the host, which H. pylori tries to down-regulate, determines 
aggressiveness of the inflammation (Robinson et al. 2007). 
 
In autoimmune gastritis, CD4+ T cells react with the adenosine triphosphatase of the gland 
cell. In some cases, molecular mimicry with H. pylori appears to trigger this autoimmune 
process (Amedei et al. 2003). Autoimmune gastritis in turn impairs acid production, which 
is needed in nonhaem dietary iron absorption. Vitamin B12 deficiency will ensue after 
deficiency in intrinsic factor (Kaptan et al. 2000). 
 
Smoking has been associated with increased atrophic change and intestinal metaplasia in 
H. pylori-positive patients (Nakamura et al. 2002). Also more dysplasia has been found 
among smokers (Kneller et al. 1992). Furthermore, smoking increases the risk for gastric 
carcinoma (Komoto et al. 1998).  However, some studies found no connections between 
smoking and atrophy or intestinal metaplasia (Ohkuma et al. 2000; Ito et al. 2003). 
Helicobacter pylori density, assessed by the UBT, has been lower among smokers 
(Moshkowitz et al. 2000). The authors speculated that the reason was the thinner mucous 
layer in the smoker’s stomach. Smoking also promotes gastric lesions and ulceration by 
increasing duodenogastric reflux, decreasing production of protective prostaglandins and 
mucus, increasing acid secretion by stimulating H2-receptors and increasing pepsinogen 
production (Bago et al. 2000; Parasher and Eastwood 2000; Tatemichi et al. 2001). 
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Peptic ulcer 
Helicobacter pylori plays a major role in PUD. In a review of 21 studies with 10146 
patients, the presence of H. pylori doubled the prevalence of a PU (odds ratio (OR) 1.81 
among NSAID users and 2.17 among nonusers). In age-matched studies, the OR was as 
high as 4.03. Helicobacter pylori-positive NSAID users have an ulcer risk 17 times higher 
than that of H. pylori negative non-NSAID users and a bleeding ulcer risk 21 times higher 
(Papatheodoridis et al. 2006). The efficacy of the eradication therapy in ulcer healing and 
prevention of ulcer relapse also suggests the H. pylori aetiology in PUD (Ford et al. 2006). 
It was estimated that 10–20% of H. pylori positives will develop a PU (Rauws and Tytgat 
1995). In a meta-analysis, 95% of PU-related risk was attributable to H. pylori, NSAIDs 
and smoking, H. pylori being the most important in the North American general population 
(Kurata and Nogawa 1997). Patients with antrum-predominant gastritis with high acid 
output and gastric metaplasia in the duodenal bulb are prone to develop a DU, whereas 
those with diffuse gastritis and perhaps atrophy are prone to develop a GU (Sipponen 
2001). Still, it should be borne in mind that H. pylori is not the only cause of PU and that 
the ulcer can relapse after successful eradication (Hobsley et al. 2006). 
 
Malignancies 
Helicobacter pylori is a strong risk factor for gastric mucosa-associated lymphoid tissue 
(MALT) lymphoma and noncardiac adenocarcinoma. As early as 1994, the World Health 
Organization classified H. pylori as a definite carcinogen. The risk of gastric cancer among 
infected patients has been estimated to be 1–2%, at least eight times higher than that 
among noninfected patients, although lower figures were also stated (Kuipers 1999; 
Sipponen and Marshall 2000).  In a large nested case-control study in Finland, H. pylori-
positives showed increased risk for noncardiac gastric cancer (OR = 7.9) and a smaller risk 
for cardiac gastric carcinoma (OR = 0.31). In a Chinese study, H. pylori was a risk factor 
for both cardiac and noncardiac adenocarcinomas HR 1.64 and 1.60 (Kamangar et al. 
2007). The pathogenic sequence of inflammation, atrophy, intestinal metaplasia, dysplasia 
and intestinal-type gastric cancer is known, but the exact mechanisms for carcinogenesis 
are still debatable (Genta and Rugge 2006). The properties of the H. pylori strain, such as 
CagA positivity, genetics of the host such as interleukin 1 gene cluster polymorphism and 
environmental factors, all appear to predispose to cancer. 
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Gastric MALT lymphomas are T-cell-dependent B-cell lymphomas (Lee et al. 2004). The 
precondition of MALT lymphoma, i.e. the presence of MALT, is always associated with 
H. pylori infection, and in more then 90% of cases, MALT lymphoma is associated with H. 
pylori (Stolte et al. 2002). Development of MALT lymphoma is still a rare event among H. 
pylori-positive patients, e.g. 0.66% in a large German study (Stolte et al. 2002). Some 
factors predisposing to the malignant change were revealed: e.g. CagA can prevent 
lymphocyte apoptosis and γ-glutamyl transpeptidase inhibits regulatory T-cell proliferation 
(Moss and Malfertheiner 2007). 
 
Dyspepsia 
Dyspepsia is a combination of symptoms referring to the upper gastrointestinal (GI) tract, 
such as abdominal pain or discomfort, abdominal bloating, postprandial fullness, early 
satiety, heartburn and acid regurgitation and vomiting. Dyspepsia is further divided into 
organic dyspepsia with a distinct aetiology and functional dyspepsia, in which the 
aetiology is still obscure. Functional dyspepsia is difficult to define. The last attempt 
(Rome III criteria) is now available for scientific use. The functional gastroduodenal 
disorders are divided into three major categories: functional dyspepsia, belching disorders, 
and nausea and vomiting disorders. Rome III considers functional dyspepsia as too 
heterogeneous a term to be studied as an entity. Instead it recommends the use of 
postprandial stress syndrome and epigastric pain syndrome (Drossman 2006).  
 
Acute H. pylori infection induces transient symptoms. Graham et al. (2004) successfully 
infected 18 healthy volunteers with a CagA-negative strain. All had mild to moderate 
symptoms, which began 3 days after inoculation, peaked between days 8 and 11 and 
resolved after 1 week. The symptoms were dyspepsia, abdominal pain, belching, halitosis, 
anorexia, chilly sensations and headache (Graham et al. 2004). In the chronic phase, 
symptoms of H. pylori infection can be assessed by symptom resolution in eradication 
studies. In several studies, the ulcer-like dyspepsia responded most favourably 
(Veldhuyzen van Zanten et al. 2002; Treiber et al. 2004; di Mario et al. 2005). Several 
possible pathophysiological mechanisms for these symptoms were proposed: smooth 
muscle dysfunction, changes in secretion of gastric acid and peptides, changes in 
nociception, and even dysfunction in the brain-gut axis (Pieramico et al. 1993; Mearin et 
al. 1995; Mc Namara et al. 2000; Lin et al. 2001). However, the findings were not 
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consistent, and for now the mechanisms have remained hypothetical (Sarnelli et al. 2003). 
The properties of the H. pylori strains, such as cagA, were associated with symptoms 
(Treiber et al. 2004). Chronic H. pylori infection cannot be attributed to any specific 
dyspeptic symptoms, although statistically it is associated with increased abdominal pain, 
nocturnal pain and heartburn, called epigastric pain syndrome by Drossman (McNamara et 
al. 2000). 
 
 
DIAGNOSIS OF HELICOBACTER PYLORI INFECTION 
Invasive tests 
Invasive tests were the first to be used in H. pylori diagnosis. The inconvenience of the 
upper GI endoscopy needed to obtain the biopsy samples for the tests led to the 
development of noninvasive tests. Other means to obtain H. pylori samples from the 
stomach have been introduced (nasogastric tube, string test and gastric brush), but they 
have not displaced endoscopy. 
 
Rapid urease test 
The rapid urease test (RUT) is based on the urease activity of H. pylori. Helicobacters in 
the gastric biopsy samples placed in the urea-containing media produce ammonia, raise the 
pH of the media and change the colour of the indicator. The RUT is the most rapid way to 
detect H. pylori infection. The most rapid modern tests give positive results in minutes, 
enabling endoscopists to begin eradication therapy immediately after endoscopy (Goh et 
al. 2007). The early tests were considered as true negatives after incubation for 24 hours. 
The biopsies for RUT are taken at the endoscopy, one from the gastric antrum and one 
from the body or fundus. Antrum biopsy alone is not enough (Bermejo et al. 2002; Abdul-
Razzak et al. 2007). When interfering factors are excluded, the sensitivity and specificity 
are over 90% (Misra et al. 1999a). However, any condition reducing H. pylori density in 
the stomach reduces the sensitivity of the test 
 
Use of PPIs, by increasing the gastric pH, makes the environment less suitable for H. 
pylori and reduces the density of the bacteria. The change is most striking in the antrum 
and helicobacters may be found only in the fundus. The habit of taking the biopsy for the 
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RUT only in the antrum is inadequate in this situation. If the patient uses PPIs, the 
sensitivity of the RUT may even fall below 50% (Yakoob et al. 2005). 
 
Bleeding from GUs or DUs or presence of blood in the stomach from any source is 
considered to decrease the sensitivity of the RUT to 60–70% (Gisbert and Abraira 2006). 
Still, the RUT was as sensitive as histology and culture in this situation. In contrast, Castro 
Fernandez et al. (2004) determined that the test was as accurate among bleeders, recent 
bleeders and nonbleeders. Use of PPIs before upper endoscopy may in part explain the 
inferiority of the results obtained with the RUT among these patients (Udd et al. 2003). 
 
The longstanding infection can lead to atrophic change, especially in the gastric antrum, 
but also in the gastric body. Subsequently, an increase in gastric pH in the body atrophy 
reduces the density of H. pylori below the detection level of the RUT (Tucci et al. 2005). 
On the other side, the nonacidic ventricle may harbour other bacteria with urease activity, 
giving false-positive results (Brandi et al. 2006). Chronic renal failure, in which the 
prevalence of H. pylori infection is lower, may also decrease the sensitivity of the RUT 
(Misra et al. 1999b). 
 
After a failed eradication therapy, H. pylori may require over 4 weeks for to recover to the 
level detected by the RUT (Laine et al. 1998). 
 
Histology 
Histology was the first means of recognizing H. pylori, preceding the other tools by over 
100 years. It is still considered the gold standard for diagnosing H. pylori infection. The 
usual procedure of taking two biopsies from the gastric antrum and body is usually 
sufficient for the diagnosis (Dixon et al. 1996). The updated Sydney system was created 
for evaluation of the biopsy samples (Dixon et al. 1996). The value of histology is not only 
based on detecting H. pylori, but also on finding atrophic gastritis and premalignant and 
malignant changes in H. pylori gastritis, in addition to other diseases not associated with H. 
pylori. In spite of undetectable H. pylori, the presence of active gastritis indicates ongoing 
infection and suggests the need for further diagnostic tests. On the other hand, a normal 
histology practically excludes the infection (Megraud and Lehours 2007) 
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The sensitivity of histology is compromised under the same conditions as with RUT. In 
atrophic gastritis the density of H. pylori can be too low to be detected. The use of PPIs 
transfers the infection to the upper part of the stomach and reduces the amount of the 
bacteria (Nakshabendi et al. 1996). Antibiotic therapies can reduce the amount of H. 
pylori. Upper GI bleeding reduces the sensitivity (Gisbert and Abraira 2006). Helicobacter 
pylori infection can be patchy and more biopsies may be needed for detection. Under these 
conditions, Giemsa and silver staining make it easier to detect H. pylori (Dixon et al. 1996; 
Anim et al. 2000; Rotimi et al. 2000). 
 
Culture 
Culturing gastric biopsies is an almost 100% specific means to find H. pylori infection. 
However, the sensitivity is lower for several reasons. Culturing a slowly growing 
microorganism under microaerophilic conditions is a demanding process, and most 
endoscopy units in Finland do not have the necessary laboratories available. The specimen 
should be transported to the remote laboratory quickly and preferably in a cool package to 
keep the bacteria viable for culture. Unless frozen, the specimen should be cultured within 
24 hours. In optimal circumstances the sensitivity can be as much as 95% (Perez-Perez 
2000; Matsukura et al. 2004; Megraud and Lehours 2007). RUT tests, which also serve as 
a transportation medium for culture, make it more convenient to obtain cultures at the first 
endoscopy. 
 
Culturing has the same problems in sensitivity as the RUT and histology. When the 
mucosal bacterial density is low, it may remain negative. In a bleeding PU the sensitivity 
was only 45% (Gisbert and Abraira 2006).  After antibiotic therapies, it is recommended to 
wait 1 month before culturing. It may require 8 weeks before culturing succeeds after 
failed eradication therapy (Laine et al. 2000). 
 
Antibiotic Resistance 
Although culturing and determining antibiotic resistance are not recommended before the 
first attempt to eradicate H. pylori, it is valuable to know the primary resistance pattern in 
the area. Based on this knowledge, we can determine the first and second antibiotic 
combination. After the second failure, culturing is recommended (Malfertheiner et al. 
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2007). Antimicrobial susceptibility is traditionally determined against metronidazole and 
clarithromycin, which are the compounds most frequently used as first-eradication therapy. 
Resistance against amoxicillin and tetracycline is very rare and does not need to be tested 
(Debets-Ossenkopp et al. 1999; Glupczynski et al. 2001; Lawson et al. 2005; Watanabe et 
al. 2005). The fluoroquinolones are emerging in H. pylori therapy, and their widespread 
use in other diseases produces resistant strains, suggesting they should also be tested 
(Bogaerts et al. 2006). The MIC for metronidazole is 8 µg/ml, for clarithromycin 1 µg/ml, 
for ciprofloxacin 1 µg/ml and for rifabutin 4 µg/ml (Glupczynski et al. 2001). Because of 
discrepancy between in vitro and in vivo resistance, the Maastricht report does not 
recommend metronidazole resistance testing in routine clinical practice (Malfertheiner et 
al. 2007).  
 
 
The disc diffusion test on an agar plate is an inexpensive, easy and reliable test in clinical 
practice. E-test is almost as inexpensive, gives an estimate of the MIC and is the test most 
used in trials.  The gold standard is agar dilution, which is laborious and used in scientific 
research. Grignon et al. (2002) compared the E-test and disc diffusion in assessing the 
sensitivity of H. pylori to macrolides and found a 100% concordance. Glupczynski et al. 
(2002) compared the E-test for clarithromycin with agar dilution and found the E-test 
reproducible and highly compatible with agar dilution (> 98% agreement within 2 log (2) 
dilution steps). In contrast, the E-test for metronidazole showed higher MICs in half of the 
strains tested. Moreover, both agar dilution and the E-test lacked reproducibility in 
assessing metronidazole sensitivity (Glupczynski et al. 2002). Mégraud et al. (1999) 
obtained similar results in the MACH 2 study.  
 
The point mutations behind clarithromycin resistance can be found with polymerase chain 
reaction (PCR) assays (Grignon et al. 2002; Oleastro et al. 2003; Moder et al. 2007). The 
test is rapid and results can be achieved in 2 days, but a specialized laboratory is needed; in 
addition unknown mutations can also be responsible for the resistance. This test has thus 
not displaced the E-test and disc diffusion. The use of the PCR to test the point mutations 
behind fluoroquinolone resistance was also developed and showed good correlation with 
agar dilution (Nishizawa et al. 2007). 
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Noninvasive tests 
Urea breath test 
The urea breath test (UBT) exploits the ability of H. pylori to hydrolyse urea into carbon 
dioxide and ammonia ((NH2)2CO + H20 → CO2 + 2NH3). Patients swallow urea, which is 
labelled either with 13C or radioactive 14C. After being hydrolysed in the stomach, the 
labelled carbon dioxide is absorbed into the bloodstream and exhaled. The concentration of 
carbon isotope is measured in the exhaled air by scintillation (14C), isotope ratio mass 
spectrometry (13C) or nondispersive isotope-selective infrared spectrometry (13C). The 
original 14C method has given way to the use of nonradioactive 13C. Infrared spectrometry 
is a less expensive nonradioactive means to obtain results (Opekun et al. 2005). Citric acid 
given with urea improves the sensitivity of the UBT by increasing the acidity around H. 
pylori, thus increasing its urease activity (Pantoflickova et al. 2003). The UBT can be used 
to diagnose H. pylori infection without upper GI endoscopy as part of the ‘test-and-treat’ 
strategy, as well as to confirm the result of the eradication therapy after 1 month. 
 
The test is easy to perform in clinical practice and the sensitivity and specificity of the 
UBT are over 95% (Gisbert and Pajares 2004). However, the same factors reduce its 
sensitivity, as with histology and culture. Antibiotics, H2-blockers and PPIs can be 
withdrawn and GI bleeding can be found, but atrophic gastritis remains unnoticed unless 
specifically sought. In atrophic body gastritis, the UBT may miss more than half of the 
cases (Kokkola et al. 2000; Lahner et al. 2004). On the other hand, nonacid stomach may 
harbour bacteria with urease activity and lead to false-positive results, as in the RUT 
(Brandi et al. 2006). Oral bacteria having urease activity may also induce a false-positive 
UBT (Peng et al. 2001). Disturbances in gastric emptying, e.g. diabetic gastroparesis and 
gastric resection, can affect the results of the UBT. However, Togashi et al. (2006) 
obtained a 79% sensitivity in gastric resection patients by giving the urea in tablet form 
and having the patients lying in the left lateral position. 13C-urea can also be measured in 
the blood with comparable accuracy (Fry et al. 2005). The UBT is the recommended tool 
in testing eradication results (Malfertheiner et al. 2007). 
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Serology 
The enzyme immunoassay (EIA) test is the most used serological test. In this method, 
antibodies in the serum of the patient reacting with antigens of H. pylori (sonicated 
bacteria or specific parts of it, e.g. flagellin, urease, CagA) are labelled with enzyme-linked 
antibodies and the enzyme activity is measured. This enables quantification of specific 
anti-H. pylori antibodies in the IgG and IgA classes. The reliability of the method is based 
on the H. pylori antigens used as a substrate, thus genetic variations of the bacteria may 
reduce the sensitivity of the test (Megraud and Lehours 2007). On the other hand, cross-
reaction with other bacteria may produce false-positive cases. This problem has been 
overcome by using more purified specific antigens. While both IgG- and IgA-type 
antibodies have been tested, the IgG type is more reliable (Laheij et al. 1998; Herbrink and 
van Doorn 2000). The sensitivity and specificity can be similar to that of the UBT, around 
95% (Oksanen et al. 1998). In a meta-analysis of commercial kits, the medians of the 
sensitivity and specificity were 92% and 83% (Laheij et al. 1998). In a small study with 
102 patients and 8 kits, the sensitivity was 93–98% and specificity 95–98% (Meijer et al. 
1997).  
 
A major advantage of serology is that the former use of antibiotics or PPIs and upper GI 
bleeding do not affect the test, in contrast to invasive tests. In gastric body atrophy, 
serology is the most reliable means of discovering H. pylori infection (Kokkola et al. 
2000). When histology shows body atrophy, serology is recommended to exclude H. 
pylori.  
 
Serology can also be used in confirming the result of H. pylori eradication therapy. A 
decrease of at least 40% in the IgG antibody level 4 months after therapy from the 
pretreatment level is diagnostic of treatment success (Kosunen et al. 1992). Since in most 
cases IgG antibodies remain detectable for years after eradication, paired serum samples 
are always needed in this context (Kosunen et al. 1992) 
 
Serology also has some drawbacks. It is not recommended for use in populations where H. 
pylori prevalence is lower than 30%, due to false-positive results. Among young children, 
the accuracy is lower than among adults (Kolho et al. 2002; Bonamico et al. 2004; 
Sherman 2004). A single blood sample after the previous eradication therapy does not 
28 
indicate whether the infection is cured or not. In clinical practice, H. pylori serology is far 
too slow for confirming the eradication results.  
 
Stool antigen test 
Stool antigen tests are based on a polyclonal or monoclonal antibody-based EIA or a rapid 
monoclonal immunochromatographic assay. The last one can be performed in 10 minutes 
in the doctors’ office. Veijola et al. (2005) compared the Premier Platinum HpSA 
(Meridian Bioscience Inc., Cincinnati, OH, USA), Amplified IDEIA HpSTAR (Dako, 
Glostrup, Denmark) and ImmunoCard STAT! HpSA (Meridian Bioscience) tests, showing 
sensitivities of 91.9%, 96.2%, and 93.0% and specificities of 95.9%, 95.9% and 88.7% in 
the primary diagnosis. After eradication therapy the figures were for sensitivity 81.3%, 
100% and 93.8% and for specificity 97.0%, 97.6% and 97.0%. However, in children 
younger than 5 years, the sensitivity was only 75% (Kalach et al. 2005). In children the 
stool antigen tests were also periodically positive, thus reducing the sensitivity of the test 
(Haggerty et al. 2005). Storing the sample at room temperature decreases the sensitivity 
after 2–3 days to 69%. A meta-analysis of 22 studies and 2499 patients showed that the 
overall sensitivity before therapy was 94% and specificity 97%. In direct comparison, 
monoclonal tests were more sensitive (95% vs. 83%). In a posteradication setting, the 
sensitivity of the monoclonal tests was 93% and specificity 96%.  Again, in direct 
comparison the monoclonal test was more sensitive (91% vs. 76%) (Gisbert et al. 2006a) 
 
Clinical use of the tests 
The various tests have different drawbacks and none can be regarded as a gold standard 
(see Table 1). The UBT is easy to perform and accurate and can be used as a primary test 
when antibiotics, PPIs, upper GI bleeding, gastric resection or gastric atrophy are not 
interfering. In these situations, serology is an option. Invasive tests and stool antigen tests 
have the same sensitivity problems as the UBT. When the upper GI endoscopy is done, 
histology is the primary test, perhaps accompanied by the RUT, if immediate eradication 
therapy is planned. Culturing is recommended after the second eradication failure. The 
stool antigen test demands less time from the health care personnel and is currently 
replacing the UBT.  
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Table 1. Clinical use of diagnostic tests for H. pylori 
 
Test Sensitivity Specificity Aspects in clinical use 
Histology > 95% 100% PPIs, bismuth and antibiotics reduce 
sensitivity 
Rapid urea test 93–97% > 95% PPIs, bismuth, antibiotics and bleeding 
reduce sensitivity. 
Culture 70–80% 100% Technically demanding 
IgG serology 85% 79% Not suitable for screening in populations 
with low H. pylori prevalence. 
Recommended for use in diagnosis in 
bleeding ulcers, atrophic gastritis and 
MALT lymphoma or when PPI 
medication has not been stopped. 
13C-urea breath test 95–100% 91–99% Accurate and easy. Suitable for screening 
and confirmation of the eradication result. 
Stool antigen test 91–98% 94–99% Suitable for screening and for 
confirmation of the eradication result. 
Faecal sample must be stored at -20 oC 
before analysis. In room temperature the 
activity decreases rapidly. 
    
 
Modified from Ables A, et al.: Update on Helicobacter pylori Treatment. Am Fam Physician. 2007 
Feb 1;75(3):351-8. 
 
 
HELICOBACTER PYLORI ERADICATION THERAPY 
Challenges in the therapy 
Helicobacter pylori lives in an acid niche, covered with mucus, where antibiotics cannot 
easily reach. Thus, even though H. pylori is sensitive to several antibiotics, only two 
antibiotics combined with a PPI or bismuth salt give satisfactory results. Resistance of H. 
pylori against the antibiotics used is the most important factor impairing the eradication 
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results (Houben et al. 1999).  Compliance is another main factor, in which the eradication 
rate was reduced from 96% to 69% when 60% of the medication was taken (Malfertheiner 
1993; Wermeille et al. 2002). As a consequence, the next regimen is faced with more 
resistant bacteria. Some studies have suggested that H. pylori is more easily eradicated in 
PUD than in NUD. However, studies with contrasting results have also been published, 
and a recent review of 22 studies could not confirm the difference between PUD and NUD 
(Huang et al. 2005). 
 
Indications for eradication therapy 
In 1996 the European Helicobacter Study Group organized in Maastricht a meeting at 
which recommendations were given for diagnosis and therapy of H. pylori. This first 
meeting regarded only PUD and low-grade gastric MALT lymphoma as unequivocal 
indications for eradication. For gastritis with severe abnormalities and former gastric 
resection for gastric cancer, the evidence was only supportive, but therapy was still 
strongly recommended for these patients. Furthermore, eradication was advised in long-
term PPI treatment of gastro-oesophageal reflux disease, functional dyspepsia, family 
history of gastric cancer, NSAID therapy, post gastric surgery for PU and if the patient so 
wishes (Malfertheiner et al. 1997). The second meeting, Maastricht 2-2000, further 
strongly recommended therapy in atrophic gastritis, for first-degree relatives of gastric 
cancer patients and if the patient so wishes (after a full consultation with their physician) 
(Malfertheiner et al. 2002). The third consensus in 2007 recommended eradication therapy 
also in investigated NUD and uninvestigated dyspepsia (Malfertheiner et al. 2007). 
  
Test-and-treat 
Upper GI endoscopy is an inconvenient procedure for patients and seldom reveals 
malignant diseases among patients younger than 45 years. An option for these patients is to 
test for the presence of H. pylori and in positive cases to undergo eradication therapy. In 
comparison to endoscopy, this procedure was cost-effective when measured by quality-
adjusted life-years with a follow-up at 1 year (Klok et al. 2005). In comparison to 
symptomatic therapy, test-and-treat was more successful with a follow-up at 6 months 
(Gisbert et al. 2004). In a study of 650 patients using long-term acid suppression therapy 
for physician-diagnosed PUD, test-and-treat patients showed less ulcer-like dyspepsia than 
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those with usual care. Still, after giving eradication therapy to H. pylori-positive patients 
(38% of the test-and-treat group), 75% in the test-and-treat group continued using acid-
reducing medication (Allison et al. 2003). In a large Finnish study, testing for and 
eradicating H. pylori reduced GI symptoms, but could not reduce the number of 
endoscopies (Färkkilä et al. 2004). The Maastricht consensus report recommends test-and-
treat strategy in dyspeptic adult patients under 45 years of age, although in population with 
a low H. pylori prevalence, empirical acid suppression is an equivalent option 
(Malfertheiner et al. 2007). 
 
First-line therapy 
To avoid development of resistance, the intention-to-treat eradication rate in the first 
eradication therapy should be at least 80%, a level not as easily achieved in clinical 
practice (Malfertheiner et al. 2007). Bismuth was the cornerstone in the first effective 
eradication regimen. Bismuth salts alone could eradicate H. pylori in 20% of cases and in 
dual therapy with amoxicillin in as many as 50%. When bismuth was combined with 
metronidazole and tetracycline, results of over 90% were achieved, but combination with 
metronidazole and amoxicillin was not as effective. However, the regimen required 2 
weeks, was elaborate to follow, not suited for young children due to the tetracycline and 
was not effective in metronidazole resistant strains (Veldhuyzen van Zanten and Sherman 
1994). The side effects and complicated regimen (over 10 tablets per day) in this triple 
therapy led to compliance problems and further to poorer eradication results (Malfertheiner 
1993). Double therapy with omeprazole and amoxicillin appeared as an alternative regimen 
with fewer side effects, but the eradication rates remained unacceptable, around 65%. 
Combination of a PPI with clarithromycin gave similar results, 76% (Schmid et al. 1999). 
 
Triple therapy with PPI and two antibiotics 
Seven-day triple therapy with a double-dose PPI and two antibiotics finally achieved 
acceptable eradication rates with tolerable amounts of side effects, and became the therapy 
of choice. PPI combined with amoxicillin and metronidazole achieved an efficacy of 80% 
and became the first-choice remedy in Finland (Färkkilä et al. 1996). However, 
metronidazole resistance decreased the eradication rate by 30–46% (Dore et al. 2000). In a 
large Finnish trial, the eradication rate was only 65.8% (Färkkilä et al. 2004). Still better 
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results were achieved when clarithromycin was substituted for metronidazole. Lengthening 
the therapy to 10–14 days slightly improved the result (Calvet et al. 2000). Clarithromycin 
resistance reduced effectiveness by 33–78% (Dore et al. 2000). In metronidazole 
resistance, PPI + metronidazole + clarithromycin was clearly better than PPI + amoxicillin 
+ metronidazole (Katelaris et al. 2000). PPI + amoxicillin 1 g  + clarithromycin 500 mg, all 
b.d. for 7 days, became the Finnish recommendation for the first-line therapy in 2002 
(http://www.kaypahoito.fi). The Maastricht recommendation accepts substitution of 
metronidazole 500 mg b.d. for amoxicillin. Although in single trials over 90% results can 
be achieved with triple therapy, in clinical practice the results are much poorer: 60–80% 
(Moayyedi et al. 2000; Della Monica et al. 2002; Buzas and Jozan 2004). Different PPIs 
are equivalent in triple therapies (Vergara et al. 2003). Sequential therapy may achieve still 
better results. Zullo et al. (2005) showed that a 10-day sequential therapy with rabeprazole 
20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg, 
clarithromycin 500 mg and tinidazole 500 mg, all b.d., for the remaining 5 days, achieved 
better eradication rates than the standard 7-day triple regimen with rabeprazole 20 mg, 
clarithromycin 500 mg and amoxicillin 1 g, all b.d. (94% vs. 80%). 
 
Ranitidine bismuth citrate  
The only bismuth product (DeNol®) was withdrawn (now available under special licence) 
from the Finnish market after PPI-based triple therapies proved their efficacy. A 
combination of pH-raising ranitidine with the helicobacter-toxic bismuth, ranitidine 
bismuth citrate (RBC), was thereafter introduced as a substitute. Length of the therapy 
impacts eradication: 60% in 4-day, 84% in 7-day and 85% in 10-day treatments (Savarino 
et al. 1999). RBC 7-day triple therapies have been compared with the corresponding PPI 
triple therapies.  The mean eradication for RBC-clarithromycin-amoxicillin, RBC-
clarithromycin-metronidazole and RBC-amoxicillin-metronidazole was 83%, 86% and 
71%. The results were comparable to those of PPI-based therapies, except that the 
combination of RBC with amoxicillin and metronidazole was better than the corresponding 
PPI combination, OR 1.65 (Gisbert et al. 2005). The reason is that in the presence of RBC, 
nitroimidazole resistance hampers less nitroimidazole-containing remedies (van der 
Wouden et al. 1999). RBC 400 mg + amoxicillin 1 g  + clarithromycin 500 mg all b.d. for 
7 days is the alternative for the first-line therapy in Finland (http://www.kaypahoito.fi). 
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Impact of resistance 
Because antibiotic resistance is the most important risk factor for eradication failure, 
clarithromycin should be avoided when the primary resistance against clarithromycin in 
the area is at least 15-20%, unless the resistance is tested. Amoxicillin should be 
substituted for metronidazole in the clarithromycin-based therapy, if local nitroimidazole 
resistance reaches 40% (Malfertheiner et al. 2007). 
 
Rescue therapies after a failure 
In two large community-based studies, the eradication rates were only 61% and 73% 
(Moayyedi et al. 2000; Vakil et al. 2004). These are the levels most probably achieved in 
clinical practice. After a failed therapy, RBC 400 mg b.d. + metronidazole 400 mg t.d. + 
tetracycline 500 mg q.d. for 7 days is recommended in Finland. The Maastricht proposition 
is to use a quadruple therapy with bismuth or, if bismuth is not available, PPI combined 
with metronidazole and amoxicillin or tetracycline (Malfertheiner et al. 2007). The third 
therapy at least should be based on the resistance analysis. 
 
Fluoroquinolones have proved their efficacy in rescue regimens and could be used in the 
third step. Levofloxacin was compared with rifabutin in a 10-day triple therapy after two 
failures with clearly better results (ITT 85% vs. 45%) (Gisbert et al. 2006b). In a meta-
analysis, levofloxacin-based therapies were better than quadruple therapies (81% vs. 73%), 
with fewer adverse effects. A 10-day regimen was better than a 7-day; thus a 10-day 
levofloxacin-amoxicillin-PPI therapy could be recommended as a third-step therapy 
(Gisbert and Abraira 2006; Gisbert and Morena 2006). Widespread use of 
fluoroquinolones will increase resistance and may impair this regimen. 
 
Strains resistant to both metronidazole and clarithromycin are a challenge. Still, effective 
choices are in use. Since metronidazole resistance is relative, a quadruple therapy with PPI, 
bismuth, metronidazole and amoxicillin or tetracycline for 14 days can achieve 80% results 
(Miehlke et al. 2003), but with numerous side effects and difficulties in compliance.  
Rifabutin 150 mg + amoxicillin 1 g + esomeprazole 30 mg b.d. for 7 days as well as 
omeprazole 40 mg + amoxicillin 1 g t.d. for 14 days achieved over 70% success in this 
situation (Miehlke et al. 2006). A 12-day therapy with rifabutin 150 mg t.d. + pantoprazole 
80 mg and amoxicillin 1 g t.d. further increased eradication to 91%, regardless of 
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metronidazole and/or clarithromycin resistance. Increasing the amoxicillin dose to 1.5 g 
further improved the result to 97% (Borody et al. 2006). Treatment with levofloxacin 500 
mg + lansoprazole 30 mg + amoxicillin 1 g b.d. for 7 days succeeded in 79% in dual-
resistant but levofloxacin-sensitive cases (Wong et al. 2006). Remarkably, in a study of 
500 patients with primary failure, eradication after up to four attempts finally succeeded in 
99.5% of the patients (Gisbert et al. 2008).  
  
 
Side effects of the eradication treatment 
In the Cochrane analysis, 22% of patients undergoing eradication therapy experienced 
adverse effects, compared with 8% in the comparison regimen group (OR 2.2). The 
frequency of individual symptoms in the therapy and comparison regimen groups was: 
diarrhoea 8% vs. 2%, nausea and vomiting 5% vs. 0.5%, skin rash 2% vs. 1%, epigastric 
pain 5% vs. 0.6%, altered taste 7% vs. 0.5%, stomatitis 2.5% vs. 0.3% and headache 4% 
vs. 3%. The differences were significant, except for headache (Ford et al. 2006). The side 
effects, especially diarrhoea, can be reduced with probiotics and the eradication results 
may likewise improve (Tong et al. 2007). 
 
Benefits from the eradication therapy 
Peptic ulcer disease 
The pros of H. pylori eradication are best shown in PUD. The Cochrane analysis of H. 
pylori eradication in PUD was published in 2006 (Ford et al. 2006). When H. pylori 
eradication therapies alone were compared with no treatment, eradication was better in DU 
healing, 76% vs. 41.5%, number needed to treat (NNT) = 2.5. In comparison of H. pylori 
eradication therapy and ulcer-healing therapy with ulcer-healing therapy alone in healing 
DU, only a small difference in favour of combination was found (NNT = 14). There was 
no difference with GU. Healed DU recurred in surveillance times of 2 months to 5 years in 
14% after eradication therapy, but in 64% without treatment (NNT = 2); in GU, the NNT 
was 2.6. In this review, eradication therapy did not relieve symptoms better than no 
therapy and in combination with ulcer-healing therapy was not better than the ulcer-healing 
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remedy alone. However, the follow-up time in these studies was only 4–6 weeks. McColl 
et al. (1998b) clearly found fewer symptoms after successful eradication in 3 months. 
 
Nonulcer dyspepsia 
Helicobacter pylori eradication in NUD has long been controversial. The OCAY study 
found no symptomatic benefit from the eradication therapy (79% eradication success) over 
placebo (Blum et al. 1998), whereas McColl et al. (1998a) found a small but significant 
benefit (symptom resolution in 21% vs. 11%); in this study, the eradication rate was 88%. 
The debate continued until the Cochrane review was published in 2003 (Moayyedi et al. 
2003), in which of 21 randomized controlled trials showed a small but significant 10% risk 
reduction in favour of eradication therapy (NNT = 14). 
 
Test-and-treat 
In assuming that the prevalence of H. pylori infection in Finland among adults under 45 
years of age is 20%, that the test used to diagnose H. pylori had a 95% sensitivity and 
specificity, and that 100 patients with uninvestigated dyspepsia were tested, we treated 19 
truely positive patients. If the true symptomatic benefit of eradication therapy over a 
placebo is 10%, only two patients of the 100 tested, derived any real symptomatic benefit 
from the therapy. On the other hand, with the 95% specificity we would treat four wrongly 
positive patients in vain. In clinical practice, the efficacy of the therapy is at best 80%; thus 
we also have four rescue therapies. We would thus have ordered 27 therapies and 127 tests 
to benefit two patients. Among older patients, H. pylori is more prevalent, but for these 
test-and-treat is not recommended. Of course, the subjective benefit will be much higher 
because the mean placebo effect in functional dyspepsia is around 40% (Musial et al. 
2007).  
 
Gastric malignancies 
Helicobacter pylori is considered the most important risk factor for noncardiac gastric 
adenocarcinoma and eradication abolishes the cytological changes leading to cancer. 
Decisional models suggest that screening and eradication therapy could be cost-effective. 
Still, eradication therapy has not proven its efficacy in reducing gastric cancer (Fuccio et 
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al. 2007). However, in the rare MALT lymphomas, the benefit of the eradication therapy is 
proved when the lymphoma is confined to the mucosa and submucosa (Stolte et al. 2002). 
In a Japanese study with 74 patients, complete remission was achieved in 56, partial 
response in 14 and no response in only 4 patients (Terai et al. 2008). In another large 
study, 84 of 90 patients achieved complete remission, while during a follow-up of median 
45 months, eight patients had a recurrence of MALT lymphoma; the presence of H. pylori 
infection was the risk factor for recurrence (Hong et al. 2006). Stolte et al. (2002) showed 
that in about 80% of cases of low-grade stage E1 lymphomas, complete remission is 
achieved with eradication therapy, with a 5% recurrence rate per year. Eradication therapy 
was effective even when H. pylori could not be found (Raderer et al. 2006). 
 
Iron deficiency anaemia 
Helicobacter pylori can cause iron-deficiency anaemia by blood loss from gastroduodenal 
lesions. Atrophic gastritis induced by H. pylori infection also impairs iron absorption by 
decreasing acid production. After H. pylori eradication, iron-deficiency anaemia was more 
successfully treated with iron supplementation (Chen and Luo 2007). 
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PRESENT STUDY 
 
 
 
AIMS OF THE PRESENT STUDY 
 
The aims of the present study were to determine the 
 
1. primary antibiotic resistance of H. pylori in primary health care in Finland, 
2. efficacy of three therapy regimens (amoxicillin + metronidazole + lansoprazole, 
amoxicillin + clarithromycin + lansoprazole and tetracycline + metronidazole and 
ranitidine bismuth citrate) in eradicating H. pylori among patients not previously 
receiving eradication therapy, 
3. side effects of the therapy, 
4. factors affecting the results of the eradication therapy and usefulness of the history 
of antibiotic use in deciding on the eradication regimen, 
5. subjective benefit from the therapy, and 
6. effect of smoking on symptoms and gastric histology in H. pylori gastritis. 
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PATIENTS 
 
A total of 23 endoscopy referral centres recruited patients into the study. The centres were 
located in bigger and smaller towns and rural areas throughout Finland and chosen to 
receive representative samples of the Finnish population (Figure 3). The endoscopy centres 
recruited RUT-positive patients referred to upper GI endoscopy from primary health care. 
 
 
Figure 3. Endoscopy units 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The inclusion criteria were: upper GI endoscopy performed, positive RUT, indications for 
eradicating H. pylori according to endoscopists and ages between 18 and 75 years. 
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The exclusion criteria were:  
1. former H. pylori eradication therapy,  
2. PPIs or H2-blockers used regularly within two weeks or antibiotic therapy within four 
weeks before endoscopy, 
3. pregnancy, real or suspected and lactation, 
4. hypersensitivity to any of the study medications for eradication therapy, 
5. confirmed or suspected malignant disease, 
6. gastric resection, 
7. advanced kidney disease (s-creatinine > 200 µmol/l), severe liver disease, any serious 
illness with expected lifetime less than 2 years and 
8. need for over 4 weeks of proton PPI or H2-blocker therapy after the eradication therapy. 
 
Initially, a total of 342 patients were recruited. At first 10 patients were excluded from 
analysis because the H. pylori infection diagnosed with the RUT could not be confirmed 
by histology or culture, leaving 332 patients for further analyses. 
 
I. In the first study evaluating H. pylori resistance in Finland, the study population was 
comprised of 292 patients. In total, 40 H. pylori-positive cases were excluded in which the 
antibiotic sensitivity of H. pylori analysed in the E-test was not available. 
 
II. In the second study analysing the different therapies for H. pylori eradication, the 
population was comprised of 329 patients, with three H. pylori-positive patients being 
excluded because the eradication result could not be assessed. 
 
III. In the third study assessing the subjective gain of H. pylori eradication, the population 
was comprised of 216 H. pylori-positive patients, whose eradication therapy was 
successful with the first attempt at therapy and who answered all the questions in the 
Gastrointestinal Symptoms Rating Scale (GSRS) before and 1 year after therapy, and for 
whom the histology of all gastric antrum and body samples was reviewed. 
 
IV. In the fourth study evaluating the effect of smoking on the immune response and on the 
degree of gastritis, 318 patients were included. Three H. pylori-positive patients were 
excluded, due to unconfirmed eradication results. Moreover, nine patients whose 
histological samples were not adequate for full analysis, and two patients whose serology 
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was not assessed, were also excluded from analysis. The patient selection as a whole is 
presented in Figure 4. 
 
 
 
Figure 4.   Study flow chart. Helicobacter pylori eradication was tested with the 13C-urea 
breath test 1 month after therapy. If patients had used antibiotics, H2-blockers or proton 
pump inhibitors before the breath test, confirmation was also by serology or histology. 
Queries were answered before and 1 year after therapy. RUT: rapid urease test 
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METHODS 
 
In the upper GI endoscopy, one biopsy sample was taken from the gastric antrum and body 
for the RUT (Pyloriset™, Orion Diagnostica, Espoo, Finland), in addition to the basic 
histologic samples (two biopsy samples from descending duodenum, gastric antrum and 
gastric body). If the RUT was positive and the investigator considered eradication therapy 
as indicated, the patient was asked to participate in the study and invited to give informed 
consent.  
 
Patients with a GU and/or DU and the nonulcer patients were separately randomized into 
the three 7-day eradication regimens: 
 
1. lansoprazole 30 mg b.d., amoxicillin 1 g b.d. and metronidazole 400 mg t.d. (LAM) 
2. lansoprazole 30 mg b.d., amoxicillin 1 g b.d. and clarithromycin 500 mg b.d. 
(LAC) 
3. ranitidine bismuth citrate 400 mg b.d., metronidazole 400 mg t.d. and tetracycline 
500 mg q.d. (RMT) 
 
If the medication was taken properly for at least 5 of the 7 days, it was considered to be 
carried out per protocol. The eradication results were assessed on an intention-to-treat 
basis. Success of the therapy was controlled 4 weeks after therapy by the UBT. If the UBT 
was negative, the patients were asked to give a blood sample for serology. If the UBT was 
positive, the patients were referred for a control endoscopy within 3 months after the first 
endoscopy with repeated histology, culture and RUT. A single pathologist (P. Sipponen) 
reviewed all the histologic samples according to the updated Sydney system.  The 
specimens were stained with haematoxylin-eosin, Alcian blue periodic-acid Schiff and 
modified Giemsa stains. 
 
Culture 
The Pyloriset™ also serves as a medium for transport to the culture. The samples were 
mailed by special delivery in a cold package to Laboratory Diagnostics of Helsinki 
University Central Hospital (HUCH) for culture the following morning. Specimens in the 
RUT were cultured on Brucella agar plates (BBL; Becton Dickinson, Cockeysville, MD, 
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USA) supplemented with horse blood (7%). Selective Brucella agar plates containing Iso-
Vitalex (1%), vancomycin (6 mg/l), amphotericin (2 mg/l) and nalidixic acid (20 mg/l) 
were used. The plates were incubated at 37 °C in a microaerobic atmosphere for a 
maximum of 12 days. The H. pylori isolates were identified based on colony appearance, 
Gram staining, and positive reactions in the catalase, oxidase and urease tests (Mégraud 
2007). 
 
Antibiotic resistance 
The MICs were determined for metronidazole and clarithromycin by the Etest™ method 
(AB Biodisk, Solna, Sweden). Colonies picked from agar plates were harvested in Müller-
Hinton (BBL) broth. The bacterial suspensions were diluted to match the turbidity of a 4-
McFarland standard. Mueller-Hinton agar plates (BBL) supplemented with 10% horse 
blood were inoculated with the suspension and the E-test strips were placed on agar plates. 
The plates were incubated at 37 °C in a microaerobic atmosphere for 72 h. The MIC values 
were determined according to manufacturer’s instructions. The breakpoint of resistance for 
clarithromycin (1 µg/ml) was determined according to the guidelines of National 
Committee for Clinical Laboratory Standards (NCCLS) and that for metronidazole (8 
µg/ml) as earlier used and suggested by King (2001). 
 
Serum antibody determination 
Serum samples taken before and over 4 months after eradication therapy were stored at -20 
°C and analysed in parallel. The H. pylori IgG and IgA antibodies were analysed with an 
in-house EIA (Oksanen et al. 1998). If the H. pylori IgG antibodies decreased at least 40%, 
eradication was considered successful (Rautelin and Kosunen 2004). 
 
Questionnaires 
At the endoscopy, the patients completed a query on previous antibiotic use, current 
medication, smoking, alcohol consumption and social situation. The GI symptoms were 
assessed, using the GSRS, which grades all symptoms during the previous week into seven 
categories (1–7) (Svedlund et al. 1988). The main concern in the analysis was in the 
symptoms that are categorized as dyspeptic symptoms in the original GSRS study: stomach 
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pain, heartburn, acid regurgitation, sucking sensation (hunger pain), and nausea and 
vomiting. These symptoms were combined to produce a total dyspeptic score. This 
questionnaire was repeated 1 year after therapy. During the therapy, the patients completed 
a diary on the use of eradication medication, side effects and other concurrent medication. 
 
Four weeks after therapy, in the UBT, the patients completed a query on their opinion of 
the endoscopy, eradication medication, and use of the antibiotics and PPIs before the UBT. 
One year after therapy, the patients were sent a questionnaire containing GSRS and 
questions about medication, alcohol consumption and smoking and possible new therapies 
for H. pylori eradication after failure of the first therapy. 
 
Statistical analyses 
The dichotomic variables were analysed with the chi-squared test or Fisher’s exact test 
when appropriate and continuous variables with the Mann-Whitney U-test. The sign test 
was used to examine symptom changes as a whole. The correlations were analysed with 
canonical correlation. Logistic regression analysis (method: forward) was used to detect 
independent factors. The statistical analyses  (I, II) were carried out with the software 
package SPSS for Windows (version 11.0, SPSS Inc., Chicago, IL, USA). NCSS 2000 
software for Windows (NCSS Statistical Software, Kaysville, UT, USA) was used for 
statistical analyses (III, IV). 
 
Ethics 
The ethics committee of HUCH and local ethics committees serving the endoscopy centres 
approved the study. All study subjects gave their informed consent and the study was 
conducted according to the Declaration of Helsinki.  All patients were given medical 
therapy already found effective in eradicating H. pylori. Only in case of therapy failure 
were patients asked to have a second upper GI endoscopy to reveal possible resistance of 
the bacteria and subsequently an effective second therapy.  
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RESULTS 
Resistance 
Of the 342 RUT-positive patients, both histology and culture were negative in 10 (3%) 
cases and these were considered as H. pylori-negative.  Of the remaining 332 patients, H. 
pylori could not be cultured in 33 cases. Furthermore, in three culture-positive cases H. 
pylori was lost before resistance determination, and in four cases resistance was 
determined only with the disc diffusion test. Finally, the 292 cases (158 women, 134 men, 
mean age 56 years, 23 had gastric and 56 duodenal ulcers) with the E-test result formed the 
study population.  
 
Resistance against metronidazole and clarithromycin was also tested with the disc 
diffusion test. The results of the disc diffusion and E-tests were 99.7% equivalent; only in 
one case did the disc diffusion show metronidazole resistance and E-test sensitivity.  
 
The metronidazole resistant cases comprised 38% of the patients (110/292), 25% (34/134) 
of the men and 48% (76/158) of the women (p < 0.001). Figure 5 shows the risk factors for 
metronidazole resistance in males and females. Previous use of antibiotics for 
gynaecological infections (67% vs. 43%, p = 0.001) and alcohol consumption increased the 
risk of resistance among women. Marital status, education and occupation did not affect 
the resistance rate. The men had no significant risk factors. Resistance was more prevalent 
in towns with over 50 000 inhabitants (44% vs. 32%in smaller towns and rural areas, p = 
0.03), but local use of nitroimidazoles, obtained from the statistics of the National Agency 
for Medicines, showed no significant correlations with resistance frequency.  
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 Figure 5. Metronidazole resistance among men and women 
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Only seven patients (2%) had a clarithromycin-resistant H. pylori strain. Clarithromycin 
resistance was clearly associated with former antibiotic therapies: use of antibiotics for 
respiratory infections increased the resistance rate from 0% to 4% (p = 0.02) and for dental 
infections from 1% to 6% (p = 0.002) (Figure 6). Patients with known previous macrolide 
therapy also had resistant strains in 8% compared with 2% in those without. The difference 
was not significant in these low frequencies (p = 0.053). 
 
 
Figure 6. Clarithromycin resistance according to previous antibiotic therapies among 
all patients 
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Only four patients harboured strains resistant to both metronidazole and clarithromycin. 
 
In multivariate logistic regression analysis, female gender (OR 2.2, 95% confidence 
interval (CI) 1.3–3.8) and previous use of antibiotics for gynaecological infections (OR 
2.5, 95% CI 1.2–54) independently predicted metronidazole resistance. Previous use of 
antibiotics for dental infections was the only independent risk factor for clarithromycin 
resistance (OR 5.4, 95% CI 1.0–28.8). 
 
Results of the eradication therapies 
The study population comprised 329 patients, of which 106 had LAM, 110 LAC and 113 
RMT therapy. The therapy groups did not differ in age, sex, PU, smoking, coffee 
consumption, NSAID or acetylsalicylic acid (ASA) use, macrolide or metronidazole 
resistance. Only alcohol consumption was significantly higher in the LAC group than in 
the others (p < 0.05). However, alcohol had no effect on the eradication results and cannot 
be regarded as a confounding factor. 
 
The eradication rate in the LAC group was 91% (100/110) in the LAM group 78% 
(83/106), and in the RMT group 81% (92/113.  The differences were statistically 
significant between LAM and LAC (p = 0.01) and between LAC and RMT (p = 0.04). 
Metronidazole resistance reduced the eradication rate in the LAM group from 93% (52/56) 
in sensitive cases to 53% (20/38), p < 0.001 and in the RMT group from 91% (58/64) to 
67% (26/39), p = 0.002 (Figure 7). Reduction caused by metronidazole resistance in the 
LAC group was not significant (from 95% to 84%). LAC therapy failed in all three 
clarithromycin-resistant cases. 
 
The history of macrolide therapy reduced the eradication rate from 86% to 67% (p = 0.002) 
and tetracycline therapy from 88% to 71% (p = 0.001). LAC therapy was most sensitive to 
former antibiotic therapies: if none of the antibiotics mentioned were used, the eradication 
rate was 98%, and if any were used, 81% (p = 0.002). Thus, when any of these antibiotics 
were used previously, RMT therapy was as effective as LAC. Antibiotic therapies against 
respiratory, dental, gynaecological and diarrhoeal infections did not predict failure; the 
only exception was dental diseases in the LAC group (79% vs. 96%, p = 0.01). Local 
consumption figures for metronidazole and clarithromycin did not predict therapy failure. 
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Figure 7.  Eradication success between therapy groups according to metronidazole 
resistance  
 
 
 
Smoking reduced the efficacy of treatment only in the LAC group: from 95% to 81%. As a 
result, all three remedies were equally efficient among smokers. Coffee consumption 
likewise impaired only the LAC therapy. Finally, all the LAC failures were persons who 
smoked and/or drank coffee. Age, gender and PUD did not affect eradication. The greater 
distribution volume of the drugs, measured by the body surface area, predicted therapy 
failure only in the LAM group. In the RMT group, 26% of the patients missed at least one 
tablet compared with 9% in the LAC and 12% LAM groups. Patients who missed at least 
one tablet in their therapy had a lower eradication rate than did those who took all the 
scheduled medication (73% vs. 86%, p = 0.04).  
 
A multivariate analysis was performed to find independent factors for eradication failure. 
Only factors known at the endoscopy were included (age, present PU, previous PU, alcohol 
use, smoking and previous therapy with amoxicillin, macrolides or tetracycline and for 
females also previous use of nitroimidazoles). Among women, previous use of 
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(OR 4.3, 95% CI 2.0–9.4). Among men, no independent risk factors for treatment failures 
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A total of 90% of patients experienced side effects; 40% at least moderate, interfering with 
daily activities. Although patients in the LAM group had mostly flatulence, in the LAC 
group taste disturbances and in the RMT group nausea and vomiting, the total side effect 
score was similar in the various treatment arms. Patients in the RMT group found it most 
difficult to take medication according to the instructions (p < 0.001 compared with the 
LAM and LAC groups). 
 
Symptomatic response to Helicobacter pylori eradication 
The success of the eradication therapy was confirmed in 275 patients. The histology was 
incomplete in nine cases and a further 50 patients did not return the query sent 1 year after 
therapy or the queries were incompletely filled. Thus, this study comprised 216 patients. 
One year after the therapy, all symptoms in the GSRS were reduced significantly. The 
mean severity of dyspeptic symptoms in the seven-category questionnaire before therapy 
was 2.64 and after 1 year 1.84 (31% reduction). The reduction was similar in each 
dyspeptic symptom. Those GSRS symptoms referring only to the lower GI tract 
(constipation, flatulence, diarrhoea, loose stools, hard stools, urgency and defective 
defecation) decreased 20%. 
 
Before therapy, the mean total dyspeptic symptom score was higher among women than 
men (13.88, 95% CI 12.90–14.85, vs. 12.52, 95% CI 11.78–13.26, p = 0.046) and also 
decreased more (4.69 (95% CI 3.76–5.61) vs. 3.33 (95% CI 2.62–4.04), p = 0.03). Patients 
50–59 years of age had slightly more severe symptoms than those younger and older (total 
dyspeptic score 14.24 (95% CI 13.21–15.27) vs. 12.63 (95% CI 11.45–13.82), p = 0.04 and 
12.72 (95% CI 11.71–13.74), p = 0.03), and there was clearly a better improvement in the 
total dyspeptic score after therapy in this group, 5.32 (95% CI 4.37–6.28) vs. 3.37 (95% CI 
2.37–4.37), p = 0.009, and 3.35 (95% CI 2.35–4.36), p = 0.003, among the younger and the 
older (Figure 8). 
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Figure 8. Total dyspeptic score decrease in five age groups 
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Duodenal ulcer was found in 28, gastric ulcer in 12, and both in 3 patients. Although 
dyspeptic symptoms did not differ significantly between duodenal ulcer and NUD patients, 
the DU patients had a more pronounced reduction in the dyspeptic symptom score (mean 
5.93 (95% CI 4.45–7.41) vs. 3.65 (95% CI 3.04–4.26), p = 0.009). Differences in 
individual symptoms are presented in figures 9 and 10. 
 
 
Figure 9. Mean severity of dyspeptic symptoms before the H. pylori eradication 
among duodenal ulcer and NUD patients 
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Figure 10. Symptom decrease after H. pylori eradication among duodenal ulcer and 
nonulcer dyspepsia patients 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
Pain Heartburn Acid regurgitation Sucking sensation Nausea and
vomiting
Sy
m
pt
o
m
 
ch
an
ge
 
 
 
 
Nonulcer dyspepsia
Duodenal ulcer
 
 
 
Although smoking did not affect the dyspeptic symptoms at baseline, the mean reduction 
in the total dyspeptic symptom score was greater among smokers (5.64 (95% CI 4.21–
7.08) vs. 3.65 (95% CI 2.98–4.32), p = 0.008). Especially abdominal pain improved more 
in smokers than in nonsmokers (1.79 (95% CI 1.30–2.27) vs. 0.78 (95% CI 0.60–0.97), p < 
0.001). 
 
Changes in the number of medication the patients used did not significantly affect 
reduction in the total dyspeptic score (major medication classes analysed: vitamins and 
trace elements, cardiovascular, gastroenterologic, gynaecologic, endocrinologic and 
metabolic drugs, NSAIDs and ASA). Alcohol and coffee consumption likewise had no 
effect on symptom changes. 
 
Gastric histology before therapy did not correlate with the total dyspeptic score, but 
patients with higher (Sydney 2-3, N = 82) antral neutrophilic inflammation had a clearly 
better symptom resolution than those with lower inflammation (Sydney 0-1, N = 134) 
(4.67 (95% CI 3.86–5.49) vs. 3.37 (95% CI 2.51–4.22), p = 0.008), while gastric body 
atrophy of any grade (N=35) had a contrasting effect (2.40 (95% CI 1.07–3.73) vs. 4.35 
(95% CI 3.70–5.00) among those 181 patients without corpus atrophy).  
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In multivariate logistic regression analysis, DU (OR 3.2; 95% CI 1.3–7.8), age from 50 to 
59 years (OR 2.2; 95% CI 1.2–3.9) and neutrophilic inflammation grade 2–3 in the gastric 
antrum (OR 1.9; 95% CI 1.1–3.3) predicted better response in the total dyspeptic score.  
 
Smoking, histology and serology 
The study population comprised 318 H. pylori-positive patients (73 smokers and 245 
nonsmokers) with confirmed eradication results and complete gastric histology. Smokers 
had less often gastric body atrophy than nonsmokers (4.1% vs. 17.1%, p = 0.004) (Figure 
11). Chronic inflammatory cell and neutrophilic inflammation were also milder in the 
gastric body in smokers. No differences were found in the gastric antrum. Compared to 
nonsmokers, smokers had a higher H. pylori load in the gastric antrum, but lower in the 
gastric body. Although body atrophy is more common in older age, and smokers were 
younger than nonsmokers, the difference was seen even when the population was divided 
into four age groups of equal size. Logistic regression analysis containing age, sex, and 
smoking, confirmed that smoking was independently associated with reduced body atrophy 
(OR=0.2, 95% CI 0.1-0.8). Smoking did not increase intestinal metaplasia in the gastric 
antrum or body. 
 
 
Figure 11. Smoking and atrophy in the gastric body 
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Smoking reduced the IgG antibody response against H. pylori, with mean titres of 5587 vs. 
8535, p = 0.002. The decrease in serum immunoglobulin levels after eradication therapy 
52 
was smaller among smokers (69% vs. 76%, p < 0.001). Likewise, serum IgA antibody 
levels decreased less after therapy among smokers (57% vs. 65%, p = 0.01). 
 
Peptic ulcer 
Of the 73 smokers, 23 (31.5%) had a DU, compared with 28 (11.4%) of the 245 
nonsmokers. A GU was found in only 8.2% of smokers and 5.7% of nonsmokers; the 
difference was nonsignificant. None of the patients with any degree of atrophy in the 
gastric body had a PU. Use of NSAIDs, ASA, coffee or alcohol did not increase the 
prevalence of PUs. 
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DISCUSSION 
Methodological aspects 
To my knowledge, this is the first prospective nationwide population-based study of 
Helicobacter pylori. The endoscopy units were chosen in bigger and smaller towns and 
rural areas, so that the population they served could represent the Finnish population as a 
whole and the results could be generalized throughout the whole nation. However, some 
selection biases may still exist. The study population was a small portion of all patients 
referred for upper GI endoscopy in these centres during the time of recruitment. Younger 
patients were more prone to have undergone H. pylori eradication, based on noninvasive 
tests, thus excluding them from the study. The recruited patients were referred for upper GI 
endoscopy; thus, they probably had more severe and persistent dyspeptic symptoms. They 
also had an indication for eradication therapy, which could select more serious cases. 
Patient selection was based on the RUT; thus patients with severe gastric atrophy might not 
have been found. The symptomatic results of therapy could also have been biased if those 
patients who did not complete the query 1 year after therapy had outcomes different from 
those who did. 
 
The UBT was used as a basic test to confirm the eradication result. The UBT can be 
unreliable in advanced atrophic gastritis (Kokkola et al. 2000). In our study, none had 
grade 3 atrophy, 6 had grade 2 atrophy and 29 grade 1 atrophy in the gastric body. Thus the 
effect on the UBT results was probably marginal. 
 
 
Antibiotic Resistance 
The sensitivity to both metronidazole and clarithromycin was polarized to the very 
sensitive and very resistant ends, leaving little room to speculate about the grey zone 
between sensitivity and resistance. In all metronidazole-sensitive cases the MICs were 
below 2 µg/ml, while among resistant cases only two had MICs near the breakpoint (12 
and 16 µg/ml). The nearest clarithromycin MICs around the breakpoint 1 µg/ml were 
0.125 and 6 µg/ml.  
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Currently when test-and-treat is recommended for dyspeptic patients under 45 years of age 
and without alarming symptoms, it is important to know the prevalence of H. pylori and 
the primary resistance pattern in the population. If primary metronidazole resistance is at 
least 40%, metronidazole-containing eradication remedies are not recommended as a 
primary therapy (Malfertheiner et al. 2007). If clarithromycin resistance rate is 15–20%, 
clarithromycin is not recommended without susceptibility testing (Malfertheiner et al. 
2007). The overall resistance to metronidazole in our study was 38%, which is slightly 
higher than in Northern part of Europe. Resistance among women was 48%, too high for 
metronidazole-based therapies. The most logical explanation for higher resistance level is 
former nitroimidazole therapy.  In this study, 69% of women remembering former 
nitroimidazole use had a resistant strain. Furthermore, in Finland, the metronidazole use in 
defined daily dose per 1000 inhabitants per day is 0.3, compared with 0.07 in Norway, 
where metronidazole resistance is 30%. Clarithromycin resistance was 2%, as low as that 
usually reported in Northern European countries (Lerang et al. 1997; Jaup et al. 1998). 
This low resistance level can be attributed to the restrictive use of macrolides in respiratory 
infections in Finland after the recommendation in 1991 (Huovinen and Klaukka 1991). In 
2001, macrolide consumption in Finland was only one third of that in France, where 
clarithromycin resistance is 20% (Cars et al. 2001; de Korwin 2004). Macrolide resistance 
is exceptionally high in children, e.g. 24% in a large European study (Koletzko et al. 
2006). 
 
Metronidazole resistance among Finnish men was 25%. Men at least 60 years of age were 
born and thus had acquired their H. pylori infection before metronidazole was on the 
market. They also very seldom receive metronidazole therapies. Thus, it can be concluded 
that the inherent metronidazole resistance of H. pylori in Finland is 25% as found among 
these men. The life style among modern women apparently is associated with more 
resistant helicobacters (young, urban and alcohol-consuming women). 
 
In the present analysis of H. pylori resistance, the patients were recruited from those 
referred for upper GI endoscopy; thus, the population was somewhat selected. However, 
all the patients with previous eradication therapy were excluded; thus, the results are 
representative of primary H. pylori resistance in Finland. 
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Based on resistance data, the Finnish recommendation to use clarithromycin and 
amoxicillin as the first-line eradication therapy is adequate. Fortunately, primary double 
resistance is very rare, only 1%, which makes it easier to find an effective metronidazole-
based therapy if the first attempt with clarithromycin fails. 
 
The results of the disc diffusion and E-tests for metronidazole and clarithromycin 
resistance were 99.7% equivalent. Thus disc diffusion can be recommended as a primary 
test in clinical practice. 
 
Eradication therapy 
For the eradication trial, two commonly used eradication therapies, LAM and LAC were 
chosen, in the dosages usually used (www.kaypahoito.fi/). The third, RMT, was an 
exception to that recommended. It was chosen to show, whether tetracycline would be 
effective when combined with RBC. If so, it would be an alternative therapy option for 
penicillin-allergic patients. 
 
Eradication therapy with clarithromycin and amoxicillin, combined with a double dose of 
PPI, showed the best results in our study. The ITT success of 91% is very high and reflects 
not only a low resistance to clarithromycin but also a high level of commitment and 
compliance of Finnish patients to the therapy. Metronidazole resistance was the most 
important factor for eradication failure. In comparison to sensitive cases, metronidazole 
resistance reduced the efficacy of LAM from 93% to 53% and that of RMT from 91% to 
67%. RBC is thought to be more effective than PPIs in eradicating metronidazole-resistant 
helicobacters. Our study also suggests this, although due to the small number of cases no 
statistically significant differences could be demonstrated. The high resistance level for 
metronidazole (48%) makes metronidazole combinations ineffective in treating H. pylori 
in Finnish women unless the sensitivity is tested. When the H. pylori strains were 
metronidazole-sensitive, all regimens were as effective (over 90%).  
 
In asking the patient about his/her former antibiotic therapies, those that gave inferior 
eradication results following the LAC therapy could be found. However, even among these 
patients, LAC was equally as effective as the other two regimens in all patients (81%). 
Among patients without history of antibiotic use, LAC eradicated all but one H. pylori 
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case, a result better than the accuracy of any test to confirm eradication. The value of 
antibiotic history is diminished because patients do not seem to remember their former 
antibiotic use. In the LAC group, all patients with therapy failure were either smokers 
and/or coffee drinkers, which can be associated with increased gastric acid production 
induced by smoking or caffeine (Boekema et al. 1999; Maity et al. 2003). In acidic 
environments, the penetration of clarithromycin into the gastric mucosa is impaired (Endo 
et al. 2001). Lin et al. (2002) found that coffee drinking led to eradication failures in 
clarithromycin-based quadruple therapy. Studies on smoking as a risk factor in eradication 
therapy revealed conflicting results (Cutler and Schubert 1993; Treiber et al. 2002). 
 
All three regimens caused many side effects; these effects, however, did not bring about 
compliance problems or reduce the efficacy of the therapy. RMT was a complex regimen 
and thus the most difficult to carry out, but the subjective difficulty had no impact on 
eradication results. As a whole, however, those who missed at least one tablet had poorer 
results, and this occurred most frequently in the RMT group. 
 
The 7-day PPI-amoxicillin-clarithromycin therapy appears to be an effective first-choice 
therapy in Finland. The clarithromycin-metronidazole combination is unfavourable, due to 
high metronidazole resistance and the risk of biresistance after a failed therapy. This study 
emphasizes that RBC and metronidazole combined with tetracycline cannot overcome the 
metronidazole resistance. 
 
 
Effect of eradication on symptoms 
The dyspeptic symptoms (abdominal pain, heartburn, acid regurgitation, sucking sensation 
(hunger pain), nausea and vomiting) in the GSRS were assessed. Although hunger pain is 
frequently associated with DU disease, in our study the symptoms did not aid in picking 
out DU patients. The overall symptom reduction after eradication therapy was 31%, the 
level usually achieved with a placebo (Moayyedi et al. 2006). The GSRS symptoms 
referring only to the lower GI tract were decreased by 20%. It can be speculated that 
antibiotic therapies can reduce abdominal symptoms by modifying the colonic bacterial 
flora. However, the mostly bacterial dysbalance after antibiotic therapies is not beneficial 
(Beaugerie and Petit 2004). In our study the changes in symptoms after therapy did not 
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differ between the therapy arms with different antibiotics. Thus, the 20% decrease was 
probably the result of a placebo, not an antibiotic effect. Based on this assumption, the net 
benefit from H. pylori eradication was 10%, as the Cochrane analysis showed among NUD 
patients. Usually, the placebo effect in functional gastroenterologic symptoms has been 
around 30% (Moayyedi et al. 2006).  
 
The study was planned to find factors that could better predict the symptomatic response to 
H. pylori eradication. Gender was not a major factor. The age of the patient was surprising. 
Patients 50–59 years of age had slightly more symptoms in the beginning and the symptom 
resolution was clearly better than among the other age groups. In other studies, the age 
effect has been controversial. If this reversed U-shape is a universal phenomenon in this 
context, the discrepancy between studies comparing older with younger patients can be 
explained. The results of the study of Malfertheiner et al. (2003) support our findings. The 
reason for the finding remains obscure; in the present study, associations with other factors 
predicting better response (smoking, DU, gastric histology) did not explain this. Duodenal 
ulcer also was an independent factor enhancing symptomatic response, especially stomach 
pain and sucking sensation. Effect of gastric ulcers was insignificant. Changes in gastric 
acid production could explain the difference. 
 
 
Smoking, symptoms and gastric histology 
Although smokers in some studies have had more dyspepsia and also poorer response to 
therapy (Nandurkar et al. 1998; Delaney et al. 2001; Wildner-Christensen et al. 2006), this 
study showed better symptom resolution among them, possibly because smokers more 
often had PUs and less often gastric body atrophy. Patients with a PU had better results 
here, as well as those without body atrophy.  In both cases, changes in acid production are 
potential explanations. Smoking, DU, gastric atrophy and gastric inflammation were 
strongly interrelated. Thus, strong factors in the univariate analyses were not independent 
risk factors in the logistic regression analysis.  Only DU, ages of 50–59 years and antral 
neutrophilic inflammation grade 2–3 remained independent factors. Smoking may be a 
major factor in determining the symptomatic response after eradication therapy, although 
probably via decrease in gastric atrophy and increase in DU. 
 
58 
Among nonsmokers, antral neutrophilic inflammation was associated with higher H. pylori 
loads, which in turn led to higher levels of acid production and possibly to dyspeptic 
acidsymptoms. After H. pylori eradication, acid production might be reduced, subsequently 
leading to alleviation of dyspepsia. Patients having more intensive neutrophilic 
inflammation had less body atrophy, and these together could lead to more intensive acid-
related symptoms and later to better symptom resolution after therapy. On the other hand, 
increased acid production may make the environment in the antrum more suitable for H. 
pylori and increase the density of H. pylori in the antrum (Karttunen et al. 1991). 
 
Smoking seemed to modify the antrum histology only by increasing the H. pylori load. In 
contrast, smoking was associated with the reduced acute and chronic inflammation, 
atrophy and H. pylori load in the gastric body. Reduced inflammation in the body can also 
lead to delayed atrophic changes among smokers. Thus, gastric inflammation and body 
atrophy do not explain the connection between smoking and gastric cancer. 
 
Smoking also reduced serum anti-H. pylori IgG levels before therapy and also the relative 
decrease in the titre after successful eradication. This probably represents a drawback to 
the serologic diagnostic of H. pylori among smokers. However, in this study only two 
patients had eradication failure according to serology and success according to the UBT. 
The first patient had no gastric atrophy, whereas the second had grade 1 antrum atrophy 
only, but both were smokers. This means only a 1% discrepancy between serology and 
UBT (3% among smokers).  
 
Smoking has been a known risk factor for PU before the H. pylori era. In H. pylori 
infection, smoking also increases the risk for DU (Parasher and Eastwood 2000). The 
mechanism by which smoking induces PUs is still debatable, although several possibilities 
have been introduced: reduced gastroduodenal motility and increased duodenogastric 
reflux with irritating bile salts, increased pepsinogen production, reduced mucus 
production and increased acid production leading to mucosal damage. Smoking also 
increases ulcerogenic reactive oxygen intermediates, endogenous vasopressin and platelet-
activating factor, which increases the damage and reduces prostaglandin synthesis, as well 
as epidermal growth factor, which enhance ulcer healing. In our study, smoking also 
preserved the mucosa in the gastric body and increased the H. pylori load in the gastric 
antrum, thus further increasing acid and pepsinogen production (Parasher and Eastwood 
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2000). Thus, the almost three times higher risk for DU among smokers, found in our study, 
could be expected. 
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CONCLUSIONS 
 
1. Metronidazole resistance of H. pylori in Finland and especially among women is 
high. Thus, metronidazole-based therapies cannot be recommended for women as a 
first-line treatment unless the sensitivity is tested beforehand. Clarithromycin 
resistance is extremely rare, but increased use of macrolide antibiotics may result in 
future change in this situation. 
 
2. PPIs combined with amoxicillin and metronidazole, as well as RBC in combination 
with metronidazole and tetracycline, are inferior to the PPI-clarithromycin-
amoxicillin combination, due to high metronidazole resistance. 
 
3. Amount of side effects was on the same level in all therapy regimens. 
 
4. Metronidazole resistance is the most important factor for eradication failure of 
metronidazole-based therapies, whereas macrolide resistance, smoking, and coffee 
drinking affected the clarithromycin-based therapy. History of antibiotic therapies 
has only limited use in deciding on the eradication regimen. 
 
5. The symptomatic response to H. pylori eradication is only modest, and in most 
respects a placebo effect. 
 
6. Smoking reduces the cellular and humoral responses to H. pylori infection, delays 
progression of atrophic gastritis in the gastric body, and almost triples the risk of 
duodenal ulcer. Smoking enhanced the subjective gain from the therapy. 
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PARTICIPATING ENDOSCOPY UNITS 
 
 
Heinolan terveyskeskus 
Torikatu 13 18100 Heinola 
 
Herttoniemen sairaala 
Sisätautipoliklinikka 
Kettutie 8 I, 00800 Helsinki 
 
Honkaharjun sairaala 
Honkaharju 4, 55800 Imatra 
 
Idänpään terveysasema 
Anttilankatu 4, 13210 Hämeenlinna 
 
Joensuun terveyskeskus 
Noljakantie 17, 80140 Joensuu 
 
Kajaanin Lääkäripalvelu 
Kauppakatu 27, 87100 Kajaani 
 
Karhulan sairaala 
Toivelinnankatu 2, 48600 Karhula 
 
Koskelan sairaala 
Sisätautiosasto 
Käpyläntie 11, 00600 Helsinki 
 
Kuusamon terveysasema 
Raistakantie 1, 93600 Kuusamo 
 
Lahden kaupunginsairaala 
Harjukatu  48, 15100 Lahti 
 
Länsi-Pohjan keskussairaala 
Sisätautien osasto 
Kauppakatu 25, 94100 Kemi 
 
Lääkäriasema Hertta 
Kiekkotie 2, 70200 Kuopio 
Mikkelin keskussairaala 
Sisätautien osasto 
Porrassalmenkatu 35-37, 50100 Mikkeli 
 
Palokan terveysasema 
Ritopohjantie 25, 40270 Palokka 
 
Porin kaupunginsairaala 
Maantiekatu 31, 28120 Pori 
 
Raahen sairaala 
Sisätautiosasto,  
Rantakatu 4, 92100 Raahe 
 
Rovaniemen terveysasema 
Sairaalakatu 1, 96100 Rovaniemi 
 
Saarijärven terveysasema 
Sairaalantie 2, 43100 Saarijärvi 
 
Seinäjoen terveyskeskus 
Huhtalantie 10, 60100 Seinäjoki 
 
Tampereen kaupungin terveyskeskus 
Hatanpään sairaala 
Hatanpäänkatu 22, 33100 Tampere 
 
Tikkurilan terveysasema 
Kielotie 11, 01300 Vantaa 
 
Turunmaan sairaala 
Sisätautiosasto 
Kaskenkatu 13, 20700 Turku 
 
Vantaan lääkärikeskus 
Jönsaksentie 6, 01600 Vantaa 60
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